Oncolys BioPharma Inc.
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Oncolys BioPharma Inc. made a loss over the last year. Oncolys BioPharma Inc. owes ¥0.28 for every ¥1 it owns. Oncolys BioPharma Inc. made a loss in each of the last two years.
Compared with Healthcare companies in Japan · latest annual results Dec 2025.
P/E ratio
LossOncolys BioPharma Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
63.09The share price is 63.09 times Oncolys BioPharma Inc.'s book value per share, higher than almost all Healthcare companies in Japan.
Market cap
¥205.5 BThe total market value of all of Oncolys BioPharma Inc.'s shares at today's price (share price × number of shares), larger than 83% of Healthcare companies in Japan. PosiCap size class: Meso Cap.
Net worth (book value)
¥3.3 BWhat Oncolys BioPharma Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
¥110.64Net worth divided by the number of shares. The share price of ¥6,980 is 63.1 times this, which is the P/B above.
Return on equity (ROE)
-110.1%Oncolys BioPharma Inc. lost 110.1% of its shareholders' money over the last year, lower than 97% of Healthcare companies in Japan.
Owes vs Owns
0.28×Oncolys BioPharma Inc. owes ¥0.28 for every ¥1 it owns (low), lower than 64% of Healthcare companies in Japan.
Dividend yield
NoneOncolys BioPharma Inc. does not currently pay a dividend.
Revenue growth
-9%Revenue fell 9% in the year to Dec 2025, and shrank 69% a year on average over 3 years.
Profit growth
LossOncolys BioPharma Inc. made a loss in each of the last two years.
Profit margin
-7209.6%Oncolys BioPharma Inc. lost ¥7210 for every ¥100 of revenue.
Interest cover
Not coveredOncolys BioPharma Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashOncolys BioPharma Inc. held ¥3.4 B more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Oncolys BioPharma Inc.: ¥205.5 B ÷ ¥3.3 B (30 Jun 2026) = 63.1.
What is Oncolys BioPharma Inc.'s return on equity?
Oncolys BioPharma Inc. lost 110.1% of its shareholders' money over the last year, lower than 97% of Healthcare companies in Japan.
How much does Oncolys BioPharma Inc. owe compared with what it owns?
Oncolys BioPharma Inc. owes ¥0.28 for every ¥1 it owns (low), lower than 64% of Healthcare companies in Japan.
Does Oncolys BioPharma Inc. pay a dividend?
No. Oncolys BioPharma Inc. does not currently pay a dividend.
Is Oncolys BioPharma Inc.'s revenue growing?
Revenue fell 9% in the year to Dec 2025, and shrank 69% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.